Sumitomo Mitsui Trust Group
RPRX icon

Sumitomo Mitsui Trust Group’s Royalty Pharma RPRX Stock Holding History

Sumitomo Mitsui Trust Group’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$66.6M Sell
1,187,943
-85,762
-7% -$4.46M 0.04% 380
2026
Q1 		$61.1M Buy
1,273,705
+5,661
+0.4% +$248K 0.04% 386
2025
Q4 		$49M Buy
1,268,044
+166,403
+15% +$6.35M 0.03% 471
2025
Q3 		$38.9M Buy
1,101,641
+207,338
+23% +$7.51M 0.02% 540
2025
Q2 		$32.2M Buy
894,303
+29,996
+3% +$994K 0.02% 571
2025
Q1 		$26.9M Sell
864,307
-88,416
-9% -$2.8M 0.02% 593
2024
Q4 		$24.3M Sell
952,723
-56,818
-6% -$1.51M 0.02% 616
2024
Q3 		$28.6M Buy
1,009,541
+15,963
+2% +$442K 0.02% 589
2024
Q2 		$26.2M Buy
993,578
+62,218
+7% +$1.72M 0.02% 593
2024
Q1 		$28.3M Sell
931,360
-87,266
-9% -$2.57M 0.02% 641
2023
Q4 		$28.6M Sell
1,018,626
-286,133
-22% -$7.86M 0.02% 634
2023
Q3 		$35.4M Sell
1,304,759
-1,130
-0.1% -$33.6K 0.03% 552
2023
Q2 		$40.1M Buy
1,305,889
+18,059
+1% +$612K 0.03% 535
2023
Q1 		$46.4M Buy
1,287,830
+279,667
+28% +$10.4M 0.03% 519
2022
Q4 		$39.8M Buy
1,008,163
+343
+0% +$14.3K 0.03% 554
2022
Q3 		$40.5M Buy
1,007,820
+3,586
+0.4% +$153K 0.03% 539
2022
Q2 		$42.2M Buy
1,004,234
+83,553
+9% +$3.43M 0.03% 564
2022
Q1 		$35.9M Buy
+920,681
New +$36.2M 0.02% 627

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Sumitomo Mitsui Trust Group's RPRX Position: Q2 2026 in Review

Sumitomo Mitsui Trust Group reduced its Royalty Pharma (RPRX) stake by 6.7% in Q2 2026, selling an estimated $4.46M and leaving 1,187,943 shares worth $66.6M. The position accounts for 0.04% of the portfolio, ranked #380.

Sumitomo Mitsui Trust Group first reported a position in RPRX in Q1 2022 and has held it in 18 quarters since. 645 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • Sumitomo Mitsui Trust Group held 1,187,943 shares of Royalty Pharma worth $66.6M as of Q2 2026.
  • Sumitomo Mitsui Trust Group sold 85,762 Royalty Pharma shares in Q2 2026, an estimated $4.46M.
  • Royalty Pharma made up 0.04% of Sumitomo Mitsui Trust Group's portfolio in Q2 2026, its #380 holding.
  • Sumitomo Mitsui Trust Group first reported a position in Royalty Pharma in Q1 2022 and has held it in 18 quarters since.
  • 645 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Sumitomo Mitsui Trust Group's 13F filing for Q2 2026, filed 30 Jul 2026.